Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Inducción de tolerancia inmunológica en microorganismos de expresión de antígenos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20141017002
Publicado:
05/10/2015
Caducidad:
20/04/2016
Resumen:
Una universidad alemana ofrece un enfoque terapéutico para enfermedades autoinmunes que también es preventivo. Este enfoque se basa en la inducción de tolerancia mediante la administración oral de microorganismos de expresión de antígenos. El enfoque ha demostrado ser seguro y efectivo en un modelo animal. La administración oral de microorganismos de expresión de antígenos es la estrategia terapéutica ideal para la prevención de enfermedades autoinmunes. Se buscan socios industriales para licenciar y continuar con el desarrollo de la tecnología.

Details

Tittle:
Induction of immunological tolerance in antigen-expressing microorganisms.
Summary:
A German university offers a therapeutic approach for auto-immune diseases that is also preventive. It is based on induction of tolerance through oral administration of antigen-expressing microorganisms. In an animal model this approach has proven to be safe and effective. Industrial partners are sought for licensing and further co-development.
Description:
Autoimmune diseases affect millions of people worldwide. They can have serious effects on life span and quality of life. Despite intensive research, the exact reasons for the onset of autoimmune diseases are still only poorly understood.

At present, therapies of autoimmune disorders mainly focus on the relief of symptoms rather than on the prevention of the underlying biological mechanism. Therefore, current therapeutic strategies are mostly restricted to immunomodulators or immune-suppressants.

A German university provides a novel preventive and therapeutic approach based on the induction of tolerance, which is a key mechanism for the prevention of autoimmunity. The induction of tolerance is achieved through the oral administration of antigen-expressing microorganisms.

In an animal model of multiple sclerosis, the severity and occurrence of the disease symptoms could be significantly reduced by feeding the mice with the safe fodder yeast Candida utilis (Torula yeast) expressing Myelin oligodendrocyte glycoprotein (MOG). Thus, the oral administration of antigen-expressing Candida utilis suppresses the cellular and humoral immune responses taking place in the gut-associated lymphoid tissue. Furthermore, the described treatment is considered to be safe, effective and simple.

Therefore, the oral administration of antigen-expressing microorganisms is an ideal therapeutic strategy for the prevention of autoimmune disorders.
Advantages and Innovations:
The treatment with antigen-expressing Candida utilis is
· Safe
· Simple
· Effective
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent pending

Partner sought

Type and Role of Partner Sought:
The university offers access to rights for commercial use via license agreements as well as the opportunity for further co-development to pharmaceutical industry and biotech companies.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06002005 Ingeniería genética
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001015 Productos farmacéuticos / medicamentos
06001009 Terapia genética - ADN